Failing the public health--rofecoxib, Merck, and the FDA

N Engl J Med. 2004 Oct 21;351(17):1707-9. doi: 10.1056/NEJMp048286. Epub 2004 Oct 6.

Author

Affiliation

¹ Cleveland Clinic Foundation, Cleveland, USA.

PMID: 15470193
DOI: 10.1056/NEJMp048286

No abstract available

Publication types

Historical Article

MeSH terms

Adverse Drug Reaction Reporting Systems
Advertising
Arthritis, Rheumatoid / drug therapy
Clinical Trials as Topic / history
Cyclooxygenase Inhibitors / adverse effects*
Cyclooxygenase Inhibitors / history
Drug Approval* / history
Drug Industry* / history
Drug Industry* / legislation & jurisprudence
History, 20th Century
History, 21st Century
Humans
Lactones / adverse effects*
Lactones / history
Myocardial Infarction / chemically induced*
Risk
Stroke / chemically induced
Sulfones
United States
United States Food and Drug Administration* / history

Substances

Cyclooxygenase Inhibitors
Lactones
Sulfones
rofecoxib